Strengthening European health systems by promoting the use of off-patent medicines was the topic of several speakers during a presentation the recent Medicines for Europe Conference, held in Sitges, Barcelona, Spain from June 29th to July 1st. The speakers noted that 70% of the drugs dispensed […]
Biosimilar Boom May be on the Horizon, Potentially Saving Patients Billions
Biosimilars, biologic generics, hold substantial promise in expanding access to lifesaving biologics, but growth has taken a while to ramp up. With 100 biosimilars currently in the pipeline, the industry may be set up for rapid growth in the next two years. With the potential influx of new […]
Amgen’s Biosimilar of Stelara Shows Promising Preliminary Results
New preliminary results show that Amgen’s biosimilar ABP 654 is effective in reducing psoriasis symptoms. ABP 654 is a biosimilar of Stelara, a drug currently improved and in use in 74 countries. Patients treated with the biosimilar experienced improvement in the psoriasis area severity […]
Febrile Neutropenia Biosimilar Provides Clinical and Economic Value
An analysis published in Future Oncology found that the biosimilar pegfilgrastim (PEG) can reduce spending in patients with febrile neutropenia (FN) as primary prophylaxis in high-risk patients with cancer. Around 60,000 patients are hospitalized with FN, with each admission costing ~$28,000. […]
US Biosimilars Market – 5 Things to Look Out for in 2022
The biosimilars market in the US has ramped up significantly in the past year, amidst rising political pressure surrounding high drug prices. This growth comes in spite of efforts from manufacturers to block the approval of biosimilars for key blockbuster drugs like Humira. In a new PharmaPhorum […]
AbbVie’s Claims of Corporate Espionage will be Investigated by US International Trade Commission
The US International Trade Commission has announced they will investigate claims that two companies planning to release a biosimilar of Humira engaged in corporate espionage. Abbvie, the manufacturer of the best-selling biologic rheumatoid arthritis drug, claims that Alvotech and Teva […]
AJMC Study: Projected US Savings from Biosimilars, 2021-2025
In a recent study published in the American Journal of Managed Care, researchers Andrew Mulcahy, PhD, and colleagues project US spending on biosimilars and estimate the total savings provided by them from 2021-2025. Mulcahy et al. estimate that biosimilars would save $38.4 billion in this time frame […]
ISPOR Webinar: The Future of Biosimilars
Biosimilars are poised to increase access to otherwise expensive therapies, but legal and regulatory hurdles abound. In an ISPOR webinar taking place on January 19th, 2022, presenters Aurelio Arias, MSc, Cate Lockhart, MS, PharmD, PhD, and Emma Foreman, BS will speak with moderator Liese Barbier […]
AMCP Partnership Forum on Biosimilars Identifies Adoption Challenges and RWE Solutions
The Academy of Managed Care Pharmacy (AMCP) Partnership Forum met in December 2020 to discuss the use of biosimilars in healthcare. The cross-disciplinary stakeholders examined barriers to biosimilar use in the United States and how real world evidence (RWE), among other strategies, can advance […]
Part 2 of AmerisourceBergen Podcast on Insulin Biosimilars Now Available
Part two of AmerisourceBergen’s podcast series on insulin biosimilars is now available. This episode features guidance for pharmacies awaiting updated biosimilar guidelines. “In part two of a two-part series on insulin biosimilars, we’ll talk about how pharmacies can prepare to dispense […]
